JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
NCT01185717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7726
Last updated 2014-06-02
Summary
The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2012-05-31
- Completion
- 2012-06-30
More Related Trials
-
TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis
NCT00228228 ·Status: UNKNOWN ·Phase: PHASE3
-
Vaccine Exposure in Patients With MS
NCT03191669 ·Status: COMPLETED
-
Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis
NCT00230204 ·Status: UNKNOWN ·Phase: PHASE1
-
Assessment of Patients With Multiple Sclerosis (MS)
NCT00001156 ·Status: COMPLETED
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT01517282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
NCT05121662 ·Status: COMPLETED
-
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
NCT01485003 ·Status: COMPLETED
-
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
NCT04682548 ·Status: COMPLETED
-
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
NCT03691077 ·Status: UNKNOWN ·Phase: PHASE3
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis
NCT03239860 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
NCT02545868 ·Status: COMPLETED ·Phase: PHASE3
-
Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells
NCT01587690 ·Status: COMPLETED
-
Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis
NCT02912897 ·Status: RECRUITING ·Phase: PHASE1
-
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
NCT01970410 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
NCT04230174 ·Status: COMPLETED ·Phase: PHASE4
-
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
NCT05081271 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Cognitive Effects of Immunomodulatory Drugs in MS
NCT00229502 ·Status: COMPLETED
-
Safety Study of GNbAC1 in Multiple Sclerosis Patients
NCT01639300 ·Status: COMPLETED ·Phase: PHASE2
-
Deciphering the Role of the Gut Microbiota in Multiple Sclerosis
NCT02580435 ·Status: UNKNOWN
-
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
NCT05197699 ·Status: TERMINATED
-
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
NCT00292253 ·Status: COMPLETED ·Phase: PHASE3
-
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
NCT05072691 ·Status: RECRUITING
-
Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus
NCT02489877 ·Status: UNKNOWN